Abstract
Background Prophylactic granulocyte colony stimulating factor (GCSF) is recommended with accelerated adjuvant chemotherapy but is expensive and causes bone pain. We have reviewed a series of patients with early breast cancer treated with accelerated 2-weekly paclitaxel without routine GCSF to assess its need. Patients and methods Patients receiving accelerated (dose dense) paclitaxel 175 mg/m2 2 weekly for 4 courses as adjuvant/neoadjuvant treatment for early breast cancer were treated electively without prophylactic GCSF, and monitored for absolute neutrophil count (ANC) before each cycle, grade and duration of neutropenia, incidence of neutropenic sepsis, treatment delays and requirements for secondary GCSF. Results were compared with prior patients given prophylactic GCSF. Results Of the 61 patients, 42 (69%) did not require prophylactic GCSF. Mild/moderate neutropenia was more common than in the prior group given GCSF, but secondary GCSF was required in only 6 (10%) patients due to grade 3 neutropenia and in 12 (20%) with grade 2 neutropenia. There were no episodes of neutropenic sepsis and no dose reduction or treatment delay was required. Conclusions Accelerated paclitaxel in breast cancer patients without prophylactic GCSF is safe, avoids side effects, reduces costs and is not associated with an increase risk of neutropenic sepsis or treatment delays.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439
Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178–1184
Smith RE, Bryant J, DeCillis A et al (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21(7):1195–1204
Hershman D, Neugut AI, Jacobson JS et al (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99(3):196–205
Le Deley MC, Suzan F, Cutuli B et al (2007) Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25(3):292–300
National Cancer Institute (2006) Common terminology criteria for adverse events v3.0. 2006 [cited; Available from: http://www.ctep.cancer.gov/forms/CTCAEv3.pdf
Perez E, Muss HB (2005) Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Williston Park) 19(14):1759–1767; discussion 1768, 1772–1774, 1777–1778
Sugarman S, Wasserheit C, Hodgman E et al (2006) A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC). Breast Cancer Res Treat Suppl 1:6084 (abstract)
Acknowledgment
Dr Monica Arnedos would like to thank the Cridlan Fund for allowing her to be part of this project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arnedos, M., Sutherland, S., Ashley, S. et al. Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer. Breast Cancer Res Treat 112, 1–4 (2008). https://doi.org/10.1007/s10549-007-9826-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9826-y